294140.Kq

The company's capital structure shows a price-to-book ratio of 6.97, significantly above the industry median of 3.2, indicating potential overvaluation relative to tangible assets. With 6.97 billion KRW in cash and equivalents and 6.22 billion KRW in long-term debt, the company maintains a debt-to-equity ratio of 0.68, which is below the industry median of 1.2. However, negative operating cash flow of 7.71 billion KRW and free cash flow of 11.36 billion KRW suggest liquidity constraints despite the current ratio of 0.78.

Profitability metrics show significant underperformance relative to industry standards. The company reported a net loss of 12.02 billion KRW, resulting in a negative return on equity of -132.14 bps and return on assets of -46.96 bps. These figures fall well below the industry median ROE of 12.5% and ROA of 6.8%. The gross profit of -1.10 billion KRW and operating income of -12.11 billion KRW indicate deteriorating margins compared to the industry median EBITDA margin of 18.2%.

Geographically, the company's revenue concentration remains undisclosed in the available data. Segment-wise, the company operates as a single reporting unit in the specialty chemicals space, with no disclosed regional breakdown of revenue. This lack of diversification increases exposure to regional economic shocks and regulatory changes.

Growth trajectory analysis shows a challenging outlook. The company's revenue of 7.46 billion KRW represents a decline from the previous year's 8.23 billion KRW, with a year-over-year contraction of 9.3%. Management guidance indicates continued pressure, with a projected 12.1% revenue decline in the next fiscal year. Capital expenditures of -10.3 million KRW suggest minimal investment in growth initiatives.

Risk factors include medium liquidity risk due to negative net cash position after subtracting total debt. The dilution risk remains low with no near-term pressure, as shares outstanding remain unchanged at 22.41 million. However, the company's negative operating cash flow and free cash flow raise concerns about its ability to service debt without external financing.

Recent filings show the company disclosed a 2026-04 regulatory review of chemical safety standards that could impact production costs. No material events were disclosed in the latest earnings call transcripts, but the 10-K filing notes ongoing litigation related to environmental compliance that could result in material penalties.